Jove
Visualize
お問い合わせ
JoVE
x logofacebook logolinkedin logoyoutube logo
JoVEについて
概要リーダーシップブログJoVEヘルプセンター
著者向け
出版プロセス編集委員会範囲と方針査読よくある質問投稿
図書館員向け
推薦の声購読アクセスリソース図書館諮問委員会よくある質問
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experimentsアーカイブ
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教員リソースセンター教員サイト
利用規約
プライバシーポリシー
ポリシー

関連する概念動画

Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

2.0K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
2.0K
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

1.2K
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
1.2K
Dementia01:30

Dementia

672
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
672
Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

2.3K
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
2.3K
Amyloid Fibrils03:03

Amyloid Fibrils

12.9K
Amyloid fibrils are aggregates of misfolded proteins.  Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils. 
Amyloid deposits were observed as early as 1639 in the liver and the spleen.   In 1854, Rudolph Virchow performed iodine staining,...
12.9K
Role of Neurotransmitters in Memory01:23

Role of Neurotransmitters in Memory

2.9K
Neurotransmitters are integral to the brain's communication system, enabling neurons to transmit signals across synapses. This chemical exchange underpins various cognitive functions, including memory processes. The role of neurotransmitters in memory is multifaceted, influencing the encoding, consolidation, and retrieval of memories through their action on different neural circuits.
 Glutamate and Synaptic Plasticity
Glutamate, the brain's main excitatory neurotransmitter, is...
2.9K

こちらも読む

関連記事

共著者、ジャーナル、引用グラフによってこの研究に関連する記事。

並び替え
Same author

Human microglial transitions at the Aβ-tau inflection point associate with divergent pathways to dementia and resilience.

Nature medicine·2026
Same author

Tracking the turning point in Alzheimer's disease.

Science (New York, N.Y.)·2026
Same author

Phagocytes as plaque catalysts: Human macrophages generate seeding-competent Aβ42 fibrils with cross-seeding activity.

Proceedings of the National Academy of Sciences of the United States of America·2026
Same author

Aβ plaques induce local pre-synaptic toxicity in human iPSC-derived neuron xenografts.

Stem cell reports·2026
Same author

The Alzheimer's therapeutic Lecanemab attenuates Aβ pathology by inducing an amyloid-clearing program in microglia.

Nature neuroscience·2025
Same author

Phagocytes as Plaque Catalysts: Human Macrophages Actively Generate Pathogenic Aβ42 Fibrils with Seeding and Cross-Seeding Potency.

bioRxiv : the preprint server for biology·2025

関連する実験動画

Updated: Mar 25, 2026

Hybrid PET/MRI Imaging of Alzheimer's Disease Based on 18F-AV-1451
05:17

Hybrid PET/MRI Imaging of Alzheimer's Disease Based on 18F-AV-1451

Published on: April 18, 2025

1.1K

アルツハイマー病

Philip Scheltens1, Kaj Blennow2, Monique M B Breteler3

  • 1Department of Neurology & Alzheimer Center, VU University Medical Center, Amsterdam, Netherlands.

Lancet (London, England)
|February 28, 2016
PubMed
まとめ

アルツハイマー病の研究は アミロイド仮説を超えて 複雑な相互作用と 初期段階の病気を 探求しています 将来の治療法では 標的型療法と ライフスタイルの介入を組み合わせて 総合的な脳健康管理を行うでしょう

さらに関連する動画

Motor and Hippocampal Dependent Spatial Learning and Reference Memory Assessment in a Transgenic Rat Model of Alzheimer's Disease with Stroke
09:45

Motor and Hippocampal Dependent Spatial Learning and Reference Memory Assessment in a Transgenic Rat Model of Alzheimer's Disease with Stroke

Published on: March 22, 2016

10.9K
Detection of Neuritic Plaques in Alzheimer's Disease Mouse Model
06:02

Detection of Neuritic Plaques in Alzheimer's Disease Mouse Model

Published on: July 26, 2011

37.6K

関連する実験動画

Last Updated: Mar 25, 2026

Hybrid PET/MRI Imaging of Alzheimer's Disease Based on 18F-AV-1451
05:17

Hybrid PET/MRI Imaging of Alzheimer's Disease Based on 18F-AV-1451

Published on: April 18, 2025

1.1K
Motor and Hippocampal Dependent Spatial Learning and Reference Memory Assessment in a Transgenic Rat Model of Alzheimer's Disease with Stroke
09:45

Motor and Hippocampal Dependent Spatial Learning and Reference Memory Assessment in a Transgenic Rat Model of Alzheimer's Disease with Stroke

Published on: March 22, 2016

10.9K
Detection of Neuritic Plaques in Alzheimer's Disease Mouse Model
06:02

Detection of Neuritic Plaques in Alzheimer's Disease Mouse Model

Published on: July 26, 2011

37.6K

科学分野:

  • 神経学
  • 神経科学
  • バイオマーカーの研究

背景:

  • 認知症の流行は 世界中で増加していますが 西洋では 血管のケアと脳の健康状態の改善により 減少している可能性があります
  • アルツハイマー病 (AD) の伝統的なアミロイド仮説は,相互作用する要因を含むより複雑な理解によって挑戦されています.
  • 確立されたバイオマーカーには,アミロイドβ42とタウが含まれている.新興候補は,アミロイドβオリゴマーとシナプスマーカーである.

研究 の 目的:

  • アルツハイマー病の研究の重要な進展を振り返る
  • 臨床前アルツハイマー病の理解と様々な疾患因子の相互作用への移行について議論する.
  • アルツハイマー病の診断と治療の戦略の進歩を探求する.

主な方法:

  • アルツハイマー病の病原性,バイオマーカー,イメージングに関する最新文献のレビュー.
  • 臨床前のADとライフスタイルの介入を含む新興研究動向の分析
  • MRI,PETスキャン,液体バイオマーカーなどの既定および新しい診断技術についての議論.

主要な成果:

  • 研究は線形的な因果関係を超えて 歳,保護性,病原性因子の 相互作用を認識しています
  • アミロイド・PETとタウ・PETは 臨床応用が有望で 診断や臨床試験の患者選択に役立ちます
  • 認知症前期におけるライフスタイル要因とアミロイドを標的とした早期の介入は 予備的な肯定的な結果を示しています

結論:

  • アルツハイマー病の研究は 病気の初期前段階に集中しています
  • ターゲットを絞った抗アルツハイマー治療とライフスタイル介入の組み合わせが将来の治療として想定されています.
  • アルツハイマー病に対する効果的な戦略の開発には 複雑に絡み合っている要因を理解することが重要です